Skip to main content

CORRECTION article

Front. Pharmacol., 14 December 2022
Sec. Experimental Pharmacology and Drug Discovery
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1117936

Corrigendum: Role of selective histone deacetylase 6 inhibitor ACY-1215 in cancer and other human diseases

This article is a correction to:

  1. Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases

    1. Read original article
Jianglei Li,Jianglei Li1,2Meihong Yu,Meihong Yu1,2Shifeng Fu,Shifeng Fu1,2Deliang Liu, Deliang Liu1,2*Yuyong Tan, Yuyong Tan1,2*
  • 1Department of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, China
  • 2Research Center of Digestive Disease, Central South University, Changsha, China

A Corrigendum on
Role of selective histone deacetylase 6 inhibitor ACY- 1215 in cancer and other human diseases

by Li J, Yu M, Fu S, Liu D and Tan Y (2022). Front. Pharmacol. 13:907981. doi: 10.3389/fphar.2022.907981

In the published article, there was an error in the Funding statement. “This work was supported by Scientific research project of Hunan Provincial Health Commission (No. 202103030980) and Graduate Research Innovation Project of Central South University.” The correct Funding statement appears below.

Funding

This work was supported by Scientific research project of Hunan Provincial Health Commission (No. 202103030980) and the Fundamental Research Funds for the Central Universities of Central South University (No. 2022ZZTS0860)”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: histone deacetylase 6, histone deacetylase inhibitor, ACY-1215, cancer, neurological diseases, inflammatory diseases

Citation: Li J, Yu M, Fu S, Liu D and Tan Y (2022) Corrigendum: Role of selective histone deacetylase 6 inhibitor ACY-1215 in cancer and other human diseases. Front. Pharmacol. 13:1117936. doi: 10.3389/fphar.2022.1117936

Received: 07 December 2022; Accepted: 08 December 2022;
Published: 14 December 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Li, Yu, Fu, Liu and Tan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yuyong Tan, tanyuyong@csu.edu.cn; Deliang Liu, deliangliu@csu.edu.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.